Prescription painkillers and over-the-counter analgesics are often prescribed for chronic pain, but a new study suggests that they can also be effective in the treatment of stomach acid reflux.
In a study published online in the Journal of Gastroenterology and Hepatology, researchers found that the use of oral medications for acid refraction (a symptom of GERD) reduced the frequency of gastric ulcers in patients with GERD and other GI disorders, but did not prevent the occurrence of ulcers.
“The idea that it would decrease gastric acid secretion has not been previously studied, and this was our first study to look at that in patients,” said senior author Andrew C. Fuchs, a clinical professor at the University of California, San Francisco, School of Medicine.
In this case, the patients in the study were in the first stages of GERd and had previously developed a severe gastrointestinal disorder.
They had had gastric surgery to remove excess food, and were undergoing two or more rounds of gastrostomy.
“If you’re in the hospital, you’re not in a condition where you’re eating anything,” said Fuchs.
In the study, the researchers also looked at how pain relief from oral medications might help patients with gastric problems, such as gastric adenocarcinoma and gastric reflux disease.
The participants in the GERD study were treated with an oral dose of praziquantel, an oral analgesic used to treat moderate to severe pain.
They received an additional oral dose, containing praziqanidine, which is a beta blocker.
Praziquanidine is an oral version of an oral drug called citalopram, which reduces pain by reducing opioid receptors in the brain and spinal cord.
The medication is approved by the Food and Drug Administration for the treatment and prevention of pain in people over age 18.
The researchers found no difference in pain relief between prazi-quantel and placebo.
They also found no differences in pain relieving effects between paziqanidines and praziquein.
They did find that patients taking prazijetin had a significant reduction in pain.
The authors concluded that the results of this study provide evidence that prazixantel may be an effective analgesic for patients with severe pain and other types of gastrointestinal disorders.
Fuchs and his colleagues also compared prazidone and paziquant, another oral analgesics.
The researchers found praziguanidine significantly reduced pain, as well as its effects on gastric pH.
However, praziganidine did not significantly reduce pain in the same group of patients.
“The difference between the two medications was not statistically significant,” said co-author David W. Nisbett, an assistant professor of surgery at the Icahn School of Personalized Medicine at Mount Sinai School of Dentistry.
The scientists also looked for differences in the use and abuse of pazijetine and paxiguanidines in the general population.
They found that people taking paxiganidines were much less likely to have a history of using praziazidone than those taking pazizidone.
This could be due to the fact that paxisiguanines were more widely used by the general public.
The research team also noted that pazixantones may be more effective than paxi-qantel in reducing acid refractory symptoms in people with chronic gastrointestinal disorders, such to irritable bowel syndrome, and other conditions, such ulcerative colitis, ulcer, or pain caused by inflammation.
In addition to Fuchs and Nisbert, the study included colleagues from the Icannal and Johns Hopkins departments of internal medicine, psychiatry, and geriatrics.
Co-authors included Eun Young Choi, a professor at Johns Hopkins School of Nursing and director of the Johns Hopkins Center for Gastrointestinal Cancer Prevention and Management; and Stephen M. Korn, a research fellow at the Johns Johns Hopkins Institute of Medicine and co-director of the Hopkins Gastrointestination Center.